Sanofi SNY NASDAQ

Sanofi (SNY) generated $10.75B in operating cash flow for fiscal year 2025. After capital expenditures of $1.86B, free cash flow was $8.89B.

Free cash flow margin was 19% of revenue. Cash conversion ratio was 1.38x, indicating earnings are backed by cash.

The company returned $4.58B in dividends and $4.83B in share buybacks to shareholders during the period.

Criteria supported by this page:

• HEALTH (83/100, Pass) — demonstrate the company can comfortably service its debt
• MOAT (90/100, Pass) — $8.89B (19% FCF margin) supports a durable competitive advantage
• INCOME (70/100) — Cash conversion ratio was 1.38x confirms earnings are backed by real cash flow

Overall SharesGrow Score: 75/100 with 5/7 criteria passed.